Economics of sirolimus-eluting stents: Drug-eluting stents have really arrived

Circulation

Volumn 110, Issue 5, 2004, Pages 472-474

  Weintraub, William S ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Editorials; Stents

Indexed keywords

CLOPIDOGREL; RAPAMYCIN;

CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELUTING STENT; EDITORIAL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; HUMANS; MYOCARDIAL REVASCULARIZATION; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TICLOPIDINE;

EID: 3543096366     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136820.77558.B1     Document Type: Editorial

References (19)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
3. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
4. Mahoney EM, Chu H. Cost-effectiveness analysis alongside clinical trials: statistical and methodologic issues. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press, Inc; 2003;123-156.
5. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin R, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
6. Weintraub WS, Ghazzal ZM, Douglas JS Jr, Liberman HA, Morris DC, Cohen CL, King SB 3rd. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 1993;87:831-840.
7. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
8. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858.
9. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
10. Steinhubl SR, Berger PB, Mana JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
11. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
12. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation. 2001;104:3039-3045.
13. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
14. Weintraub WS, Krumholz H. Cost-effective strategies in cardiology. In: Fuster V, Alexander RW, O'Rourke RA, Roberts R, King SBI, Wellens H, eds. Hurst's The Heart. 10th ed. New York, NY: McGraw-Hill; 2001:2487-2512.
15. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37:2240-2245.
16. Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC, McKay CR, Weintraub WS. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002;39:1096-1103.
17. Holmes DR Jr, Firth BG, Wood DL. Paradigm shifts in cardiovascular medicine. J Am Coll Cardiol. 2004;43:507-52.
18. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518.
19. Mark DB. Economics of therapy for acute coronary syndromes. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press, Inc; 2003:173-185.